CLASS II Device recall · Reported 22 Aug 2018 · FDA Enforcement Report

G8 Automated Hplc Analyzer: Hlc-723G8-ST recalled by Tosoh Bioscience

Tosoh Bioscience is recalling G8 Automated Hplc Analyzer: Hlc-723G8-ST, 021560, distributed nationwide in the US. The recall was initiated on 6 Jun 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll active analyzers with Version 5.23 Software
Quantity recalled665

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2745-2018
FDA event ID
80257
Recalling firm
Tosoh Bioscience, Grove City, OH
Classification
Class II
Status
Terminated
Recall initiated
6 Jun 2018
FDA classified
10 Aug 2018
Reported
22 Aug 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

6 Jun 2018Recall initiated by company
10 Aug 2018Classified by FDA+65 days
22 Aug 2018Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

HbAE is known to interfere with the HbA1c assay on the current version of software, Ver. 5.23. Customers should exercise caution when reviewing chromatograms and ensure that Flag 43 is enabled on their device to avoid reporting invalid test results in the presence of HbAE.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

G8 Automated HPLC Analyzer: HLC-723G8-ST, 021560; and HLC-723G8-LA, 021674 Product Usage: The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 is intended for in vitro diagnostic use for the quantitative measurement of % hemoglobin A1c (HbA1c) (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in whole blood specimens. This test is to be used as an aid in diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes.

Where it was distributed

Worldwide Distributed - US Nationwide. and the countries of Foreign distribution to Brazil, Caribbean, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, and Uruguay.

Nationwide

Questions about this recall

Why was it recalled?

HbAE is known to interfere with the HbA1c assay on the current version of software, Ver. 5.23. Customers should exercise caution when reviewing chromatograms and ensure that Flag 43 is enabled on their device to avoid reporting invalid test results in the presence of HbAE.

Which lots are affected?

All active analyzers with Version 5.23 Software

Where was it sold?

Worldwide Distributed - US Nationwide. and the countries of Foreign distribution to Brazil, Caribbean, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, and Uruguay.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Tosoh Bioscience

All 74

Other Test Kits & Diagnostics recalls

All 2,663